Arginine: Glycine amidinotransferase (AGAT) deficiency: Clinical features and long term outcomes in 16 patients diagnosed worldwide

Sylvia Stockler-Ipsiroglu, Delia Apatean, Roberta Battini, Suzanne DeBrosse, Kimberley Dessoffy, Simon Edvardson, Florian Eichler, Katherine Johnston, David M. Koeller, Sonia Nouioua, Meriem Tazir, Ashok Verma, Monica Dowling, Klaas J. Wierenga, Andrea M. Wierenga, Victor Zhang, Lee Jun C Wong

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Arginine:glycine aminotransferase (AGAT) (GATM) deficiency is an autosomal recessive inborn error of creative synthesis. Objective: We performed an international survey among physicians known to treat patients with AGAT deficiency, to assess clinical characteristics and long-term outcomes of this ultra-rare condition. Results: 16 patients from 8 families of 8 different ethnic backgrounds were included. 1 patient was asymptomatic when diagnosed at age 3. weeks. 15 patients diagnosed between 16. months and 25. years of life had intellectual disability/developmental delay (IDD). 8 patients also had myopathy/proximal muscle weakness. Common biochemical denominators were low/undetectable guanidinoacetate (GAA) concentrations in urine and plasma, and low/undetectable cerebral creatine levels. 3 families had protein truncation/null mutations. The rest had missense and splice mutations.Treatment with creatine monohydrate (100-800. mg/kg/day) resulted in almost complete restoration of brain creatine levels and significant improvement of myopathy. The 2 patients treated since age 4 and 16. months had normal cognitive and behavioral development at age 10 and 11. years. Late treated patients had limited improvement of cognitive functions. Conclusion: AGAT deficiency is a treatable intellectual disability. Early diagnosis may prevent IDD and myopathy. Patients with unexplained IDD with and without myopathy should be assessed for AGAT deficiency by determination of urine/plasma GAA and cerebral creatine levels (via brain MRS), and by GATM gene sequencing.

Original languageEnglish (US)
JournalMolecular Genetics and Metabolism
DOIs
StateAccepted/In press - Sep 4 2015

Fingerprint

Creatine
Muscular Diseases
Glycine Transaminase
Intellectual Disability
Brain
Plasmas
Restoration
Arginine
Muscle
Genes
Urine
glycine amidinotransferase
Arginine:Glycine Amidinotransferase Deficiency
Muscle Weakness
Missense Mutation
Cognition
Early Diagnosis
Proteins
Physicians
Mutation

Keywords

  • Cerebral creatine deficiency
  • GATM
  • Intellectual disability
  • Myopathy

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Arginine : Glycine amidinotransferase (AGAT) deficiency: Clinical features and long term outcomes in 16 patients diagnosed worldwide. / Stockler-Ipsiroglu, Sylvia; Apatean, Delia; Battini, Roberta; DeBrosse, Suzanne; Dessoffy, Kimberley; Edvardson, Simon; Eichler, Florian; Johnston, Katherine; Koeller, David M.; Nouioua, Sonia; Tazir, Meriem; Verma, Ashok; Dowling, Monica; Wierenga, Klaas J.; Wierenga, Andrea M.; Zhang, Victor; Wong, Lee Jun C.

In: Molecular Genetics and Metabolism, 04.09.2015.

Research output: Contribution to journalArticle

Stockler-Ipsiroglu, S, Apatean, D, Battini, R, DeBrosse, S, Dessoffy, K, Edvardson, S, Eichler, F, Johnston, K, Koeller, DM, Nouioua, S, Tazir, M, Verma, A, Dowling, M, Wierenga, KJ, Wierenga, AM, Zhang, V & Wong, LJC 2015, 'Arginine: Glycine amidinotransferase (AGAT) deficiency: Clinical features and long term outcomes in 16 patients diagnosed worldwide', Molecular Genetics and Metabolism. https://doi.org/10.1016/j.ymgme.2015.10.003
Stockler-Ipsiroglu, Sylvia ; Apatean, Delia ; Battini, Roberta ; DeBrosse, Suzanne ; Dessoffy, Kimberley ; Edvardson, Simon ; Eichler, Florian ; Johnston, Katherine ; Koeller, David M. ; Nouioua, Sonia ; Tazir, Meriem ; Verma, Ashok ; Dowling, Monica ; Wierenga, Klaas J. ; Wierenga, Andrea M. ; Zhang, Victor ; Wong, Lee Jun C. / Arginine : Glycine amidinotransferase (AGAT) deficiency: Clinical features and long term outcomes in 16 patients diagnosed worldwide. In: Molecular Genetics and Metabolism. 2015.
@article{7d9d6ef7e77c4f3baafebab44307b1fc,
title = "Arginine: Glycine amidinotransferase (AGAT) deficiency: Clinical features and long term outcomes in 16 patients diagnosed worldwide",
abstract = "Background: Arginine:glycine aminotransferase (AGAT) (GATM) deficiency is an autosomal recessive inborn error of creative synthesis. Objective: We performed an international survey among physicians known to treat patients with AGAT deficiency, to assess clinical characteristics and long-term outcomes of this ultra-rare condition. Results: 16 patients from 8 families of 8 different ethnic backgrounds were included. 1 patient was asymptomatic when diagnosed at age 3. weeks. 15 patients diagnosed between 16. months and 25. years of life had intellectual disability/developmental delay (IDD). 8 patients also had myopathy/proximal muscle weakness. Common biochemical denominators were low/undetectable guanidinoacetate (GAA) concentrations in urine and plasma, and low/undetectable cerebral creatine levels. 3 families had protein truncation/null mutations. The rest had missense and splice mutations.Treatment with creatine monohydrate (100-800. mg/kg/day) resulted in almost complete restoration of brain creatine levels and significant improvement of myopathy. The 2 patients treated since age 4 and 16. months had normal cognitive and behavioral development at age 10 and 11. years. Late treated patients had limited improvement of cognitive functions. Conclusion: AGAT deficiency is a treatable intellectual disability. Early diagnosis may prevent IDD and myopathy. Patients with unexplained IDD with and without myopathy should be assessed for AGAT deficiency by determination of urine/plasma GAA and cerebral creatine levels (via brain MRS), and by GATM gene sequencing.",
keywords = "Cerebral creatine deficiency, GATM, Intellectual disability, Myopathy",
author = "Sylvia Stockler-Ipsiroglu and Delia Apatean and Roberta Battini and Suzanne DeBrosse and Kimberley Dessoffy and Simon Edvardson and Florian Eichler and Katherine Johnston and Koeller, {David M.} and Sonia Nouioua and Meriem Tazir and Ashok Verma and Monica Dowling and Wierenga, {Klaas J.} and Wierenga, {Andrea M.} and Victor Zhang and Wong, {Lee Jun C}",
year = "2015",
month = "9",
day = "4",
doi = "10.1016/j.ymgme.2015.10.003",
language = "English (US)",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Arginine

T2 - Glycine amidinotransferase (AGAT) deficiency: Clinical features and long term outcomes in 16 patients diagnosed worldwide

AU - Stockler-Ipsiroglu, Sylvia

AU - Apatean, Delia

AU - Battini, Roberta

AU - DeBrosse, Suzanne

AU - Dessoffy, Kimberley

AU - Edvardson, Simon

AU - Eichler, Florian

AU - Johnston, Katherine

AU - Koeller, David M.

AU - Nouioua, Sonia

AU - Tazir, Meriem

AU - Verma, Ashok

AU - Dowling, Monica

AU - Wierenga, Klaas J.

AU - Wierenga, Andrea M.

AU - Zhang, Victor

AU - Wong, Lee Jun C

PY - 2015/9/4

Y1 - 2015/9/4

N2 - Background: Arginine:glycine aminotransferase (AGAT) (GATM) deficiency is an autosomal recessive inborn error of creative synthesis. Objective: We performed an international survey among physicians known to treat patients with AGAT deficiency, to assess clinical characteristics and long-term outcomes of this ultra-rare condition. Results: 16 patients from 8 families of 8 different ethnic backgrounds were included. 1 patient was asymptomatic when diagnosed at age 3. weeks. 15 patients diagnosed between 16. months and 25. years of life had intellectual disability/developmental delay (IDD). 8 patients also had myopathy/proximal muscle weakness. Common biochemical denominators were low/undetectable guanidinoacetate (GAA) concentrations in urine and plasma, and low/undetectable cerebral creatine levels. 3 families had protein truncation/null mutations. The rest had missense and splice mutations.Treatment with creatine monohydrate (100-800. mg/kg/day) resulted in almost complete restoration of brain creatine levels and significant improvement of myopathy. The 2 patients treated since age 4 and 16. months had normal cognitive and behavioral development at age 10 and 11. years. Late treated patients had limited improvement of cognitive functions. Conclusion: AGAT deficiency is a treatable intellectual disability. Early diagnosis may prevent IDD and myopathy. Patients with unexplained IDD with and without myopathy should be assessed for AGAT deficiency by determination of urine/plasma GAA and cerebral creatine levels (via brain MRS), and by GATM gene sequencing.

AB - Background: Arginine:glycine aminotransferase (AGAT) (GATM) deficiency is an autosomal recessive inborn error of creative synthesis. Objective: We performed an international survey among physicians known to treat patients with AGAT deficiency, to assess clinical characteristics and long-term outcomes of this ultra-rare condition. Results: 16 patients from 8 families of 8 different ethnic backgrounds were included. 1 patient was asymptomatic when diagnosed at age 3. weeks. 15 patients diagnosed between 16. months and 25. years of life had intellectual disability/developmental delay (IDD). 8 patients also had myopathy/proximal muscle weakness. Common biochemical denominators were low/undetectable guanidinoacetate (GAA) concentrations in urine and plasma, and low/undetectable cerebral creatine levels. 3 families had protein truncation/null mutations. The rest had missense and splice mutations.Treatment with creatine monohydrate (100-800. mg/kg/day) resulted in almost complete restoration of brain creatine levels and significant improvement of myopathy. The 2 patients treated since age 4 and 16. months had normal cognitive and behavioral development at age 10 and 11. years. Late treated patients had limited improvement of cognitive functions. Conclusion: AGAT deficiency is a treatable intellectual disability. Early diagnosis may prevent IDD and myopathy. Patients with unexplained IDD with and without myopathy should be assessed for AGAT deficiency by determination of urine/plasma GAA and cerebral creatine levels (via brain MRS), and by GATM gene sequencing.

KW - Cerebral creatine deficiency

KW - GATM

KW - Intellectual disability

KW - Myopathy

UR - http://www.scopus.com/inward/record.url?scp=84952837640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952837640&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2015.10.003

DO - 10.1016/j.ymgme.2015.10.003

M3 - Article

C2 - 26490222

AN - SCOPUS:84952837640

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

ER -